

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience

Dai Chihara,¹ Luuk Gras,² Nienke Zinger,³ Nicolaus Kröger,⁴ Jiri Mayer,⁵ Jakob Passweg,⁶ Régis Peffault de Latour,⁷ Jenny Byrne,⁸ William Krüger,⁹ Jan-Paul Bohn,¹⁰ Uwe Platzbecker,¹¹ Igor Wolfgang Blau,¹² Francesca Bonifazi,¹³ Grzegorz Helbig,¹⁴ Andrew McDonald,¹⁵ Martin Mistrik,¹⁶ Mohamad Mohty,¹⁷ Ron Ram,¹⁸ Jaime Sanz,¹⁹ Carlos Vallejo Llamas,²⁰ Robert J. Kreitman,²¹ Patrick J. Hayden,²² Donal McLornan,²³ Olivier Tournilhac,²⁴ Michel van Gelder²⁵ and Ibrahim Yakoub-Agha²⁶

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²EBMT Statistical Unit, Leiden, the Netherlands; ³EBMT Study Unit, Leiden, the Netherlands; ⁴University Hospital Eppendorf, Hamburg, Germany; ⁵University Hospital Brno, Brno, Czech Republic; ⁶University Hospital Basel, Basel, Switzerland; ⁷Hopital St. Louis 207, Paris, France; ⁸Nottingham University, Nottingham, UK; ⁹Klinik fuer Innere Medizin C, Greifswald, Germany; ¹⁰University Hospital Innsbruck, Innsbruck, Austria; ¹¹Medical Clinic and Polyclinic 1, Leipzig, Germany; ¹²Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany; ¹³IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ¹⁴Silesian Medical University, Katowice, Poland; ¹⁵Alberts Cellular Therapy, Netcare Pretoria East Hospital, Pretoria, South Africa; ¹⁶University Hospital, Bratislava, Slovak Republic; ¹⁷Sorbonne University, Saint-Antoine Hospital, AP-HP, and INSERM UMRs 938, Paris, France; ¹⁸Tel Aviv Sourasky Medical Center and Sourasky Faculty of Medicine, Tel Aviv, Israel; ¹⁹University Hospital La Fe, Valencia, Spain; ²⁰Hospital Universitario Donostia, S Sebastian, Spain; ²¹Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; ²²Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland; ²³University College London Hospitals NHS Trust, London, UK; ²⁴Department of Hematology and Cell Therapy, CHU Estaing, Université Clermont Auvergne, Clermont-Ferrand, France; ²⁵University Hospital Maastricht, Maastricht, the Netherlands and ²⁶CHU de Lille, Univ Lille, INSERM U1286, Lille, France

Correspondence:

D. CHIHARA - DChihara@mdanderson.org

O. TOURNILHAC - otournilhac@chu-clermontferrand.fr

<https://doi.org/10.3324/haematol.2022.281754>

Supplemental table 1. Treatment list in each line. Data was available for 11 patients.

| | | N (%) |
|-----------|------------------------------|-----------|
| 1st line | 2-CdA/Cladribine | 6 (54.5) |
| | Interferon-a | 3 (27.3) |
| | Interferon | 1 (9.1) |
| | CHOP | 1 (9.1) |
| 2nd line | 2-CdA/Cladribine | 4 (44.4) |
| | Interferon | 1 (11.1) |
| | Pentostatin | 1 (11.1) |
| | Rituximab (CD20) | 1 (11.1) |
| | SC | 1 (11.1) |
| | 2-CdA/Cladribine + Amsacrine | 1 (11.1) |
| | | |
| 3rd line | 2-CdA/Cladribine | 2 (22.2) |
| | Interferon-a | 1 (11.1) |
| | Nipent | 1 (11.1) |
| | Pentostatin | 1 (11.1) |
| | Rituximab (CD20) | 3 (33.3) |
| | VACOP-B | 1 (11.1) |
| | | |
| 4th line | 2-CdA/Cladribine | 1 (11.1) |
| | Interferon-a | 2 (22.2) |
| | Interferon | 1 (11.1) |
| | Rituximab (CD20) | 3 (33.3) |
| | Pentostatin + Rituximab | 1 (11.1) |
| | DEXA-BEAM | 1 (11.1) |
| | | |
| 5th line | 2-CdA/Cladribine | 2 (25.0) |
| | Interferon-a | 1 (12.5) |
| | Interferon | 1 (12.5) |
| | Prednisone | 1 (12.5) |
| | Vemurafenib | 1 (12.5) |
| | Bendamustin + Rutiximab | 1 (12.5) |
| | R-CHOP | 1 (12.5) |
| | | |
| 6th line | 2-CdA/Cladribine | 1 (14.3) |
| | Clexane | 1 (14.3) |
| | Ibrutinib | 1 (14.3) |
| | Rituximab (CD20) | 1 (14.3) |
| | Vemurafenib | 1 (14.3) |
| | R-DHAX | 1 (14.3) |
| | VACOP-B | 1 (14.3) |
| | | |
| 7th line | Ofatumumab | 1 (50.0) |
| | Rituximab (CD20) | 1 (50.0) |
| | Ofatumumab | 1 (100.0) |
| 9th line | Dabrafenib + Trametinib | 1 (100.0) |
| 10th line | Nivolumab | 1 (100.0) |